<DOC>
	<DOCNO>NCT01715441</DOCNO>
	<brief_summary>The aim multicenter randomize phase II trial determine efficacy sorafenib irinotecan combination versus irinotecan monotherapy versus sorafenib monotherapy metastatic colorectal cancer patient KRAS mutate tumor failure active drug know effective .</brief_summary>
	<brief_title>Sorafenib Combination With Irinotecan Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male female ≥ 18 year old Histologically confirm diagnosis colorectal cancer Asymptomatic resect primary tumor Metastatic colorectal cancer patient eligible curative surgery At least one target lesion : Unidimensionally measurable crosssectional imaging In area previously irradiate Disease progression failure active drug ( 5Fu 5Fu prodrugs , irinotecan , oxaliplatin , bevacizumab ) Patients bone metastasis eligible measurable lesion WHO performance status ≤ 2 Confirmation KRAS mutation codon 12 13 primary tumor metastasis Total bilirubin ≤ 1.5 ULN , ALT AST ≤ 2.5 ULN ( &lt; 5 case liver impairment ) Haemoglobin ≥ 10 g/dL , neutrophils ≥ 1,500/mm3 , platelet ≥ 100,000/mm3 Serum creatinine ≤ 1.5 ULN Negative pregnancy test woman childbearing potential Use effective contraceptive method whole treatment 3 month completion treatment male females Life expectancy least 3 month Informed consent sign prior study specific procedure Tumor evaluation perform within 3 week prior start treatment History Gilbert 's syndrome Symptomatic brain metastasis carcinomatous meningitis Boneonly metastases History presence cancer within past 5 year ( except curatively treat nonmelanoma skin cancer situ cervical cancer ) Prior surgery radiotherapy within 4 week enter study Cardiac arrhythmia require treatment ( except betablockers digoxin ) , unstable cardiac disease , myocardial infarction within previous 6 month , &gt; grade II NYHA heart failure , uncontrolled hypertension Kalemia low normal serum potassium value From ECG , QTc interval &gt; 470 ms History acute chronic pancreatitis History epileptic seizure require longterm anticonvulsant therapy History organ transplantation use immunosuppression therapy Severe bacterial fungal infection ( Grade &gt; 2 NCICTCAE v.4.0 ) Known HIV infection Longterm use CYP 3A4 enzymeinducing agent rifampicin , St. John 's Wort ( hypericum perforatum ) , phenytoin , carbamazepine , phenobarbital , dexamethasone , ketoconazole Pregnant breastfeed woman Bowel malabsorption extend bowel resection could affect absorption sorafenib , occlusive syndrome , inability take oral medication Inflammatory bowel disease chronic diarrhea ( NCICTCAE v.4.0 ) Participation another clinical trial 30 day prior study entry Concurrent treatment investigational product anticancer therapy ( except irinotecan sorafenib ) Psychological , social , geographical disorder condition would preclude study compliance ( treatment administration study followup ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Metastatic colorectal cancer patient</keyword>
	<keyword>KRAS mutation</keyword>
	<keyword>Sorafenib</keyword>
</DOC>